c16g2
Peptideexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02044081)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cell membraneDISRUPTING AGENT
Cell membrane disrupting agent
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297712 ↗
Also known as
- c16g2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03196219 | Phase 2 | Jun 28, 2017 | C3J Therapeutics |
| NCT03052842 | Phase 2 | Feb 9, 2017 | Agility Clinical, Inc., C3J Therapeutics, E Squared Trials and Registries, Inc., Vantage Data Designs, Inc. |
| NCT03004365 | Phase 2 | Jan 27, 2017 | C3J Therapeutics |
| NCT02594254 | Phase 2 | Nov 1, 2015 | Agility Clinical, Inc., C3J Therapeutics, New York University, Synteract, Inc., Vantage Data Designs, Inc. |
| NCT02509845 | Phase 2 | Jul 1, 2015 | C3J Therapeutics, New York University |
| NCT02254993 | Phase 2 | Oct 1, 2014 | C3J Therapeutics |
| NCT02044081 | Phase 2 | Feb 1, 2014 | C3J Therapeutics, Jean Brown Research |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| C3J Therapeutics | For profit | 7 | 7 | 1 | 2014 |
| Agility Clinical, Inc. | For profit | 2 | 0 | 1 | 2015 |
| New York University | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Vantage Data Designs, Inc. | For profit | 2 | 0 | 1 | 2015 |
| E Squared Trials and Registries, Inc. | For profit | 1 | 0 | 1 | 2017 |
| Jean Brown Research | For profit | 1 | 0 | 1 | 2014 |
| Synteract, Inc. | For profit | 1 | 0 | 1 | 2015 |
7 organizations
Page 1 / 1